68-4

111/136

Ishikawa T, Moriya A, Tani J, Morishita A, Ogawa C, Tachi Y, Ikeda H, Yamashita N, Yasuda S, Chuma M, Tsutsui A, Hiraoka A, Ikegami T, Genda T, Tsubota A, Masaki T, Iwakiri K, Kumada T, Tanaka Y, Okanoue T: Marked heterogeneity in the diagnosis of compensated cirrhosis of patients with chronic hepatitis C virus infection in a real-world setting: A large, multicenter study from Japan. J Gastroenterol Hepatol, 2020; 35: 1420-1425. 43) Toyoda H, Atsukawa M, Watanabe T, Nakamuta M, Uojima H, Nozaki A, Takaguchi K, Fujioka S, Iio E, Shima T, Akahane T, Fukunishi S, Asano T, Michitaka K, Tsuji K, Abe H, Mikami S, Okubo H, Okubo T, Shimada N, Ishikawa T, Moriya A, Tani J, Morishita A, Ogawa C, Tachi Y, Ikeda H, Yamashita N, Yasuda S, Chuma M, Tsutsui A, Hiraoka A, Ikegami T, Genda T, Tsubota A, Masaki T, Tanaka Y, Iwakiri K, Kumada T: Real-world experience of 12-week direct-acting anti-viral regimen of glecaprevir and pibrentasvir in patients with chronic hepatitis C virus infection. J Gastroenterol Hepatol, 2020; 35: 855-861. 44) Takeda T, Asaoka D, Nojiri S , Nishiyama M, Ikeda A, Yatagai N, Ishizuka K, Hiromoto T, Okubo S, Suzuki M, Nakajima A, Nakatsu Y, Akazawa Y, Izumi K, Matsumoto K, Ueyama H, Sasaki H, Shimada Y, Matsumoto K, Osada T, Hojo M, Kato M, Nagahara A: Linked Color Imaging and the Kyoto Classification of Gastritis: Evaluation of Visibility and Inter-Rater Reliability. Digestion, 2020; 101: 598-607. 45) Sato S, Sato S, Tsuzura F, Ikeda Y, Hayashida S, Takahashi S, Amano N, Murata A, Shimada Y, Iijima K, Nagahara A, Genda T: Elevated serum procalcitonin levels and their associa-tion with the prognosis of patients with liver cirrhosis. Eur J Gastroenterol Hepatol, 2020; 32: 1222-1228. 46) Murata A, Amano N, Sato S, Tsuzura H, Tomishima K, Sato S, Matsumoto K, Shimada Y, Iijima K, Genda T: On-treatment Serum Mac-2 Binding Protein Glycosylation Lsomer (M2BPGi) Level and Risk of Hepatocellular Carcinoma Development in Patients with Chronic Hepatitis B during Nucleot(s)ide Analogue Therapy. Int J Mol Sci, 2020; 21: 2051. 47) Asaoka D, Takeda T, Inami Y, Abe D, Shimada Y, Matsumoto K, Ueyama H, Matsumoto K, Komori H, Akazawa Y, Osada T, Hojo M, Nagahara A: The Association between Frailty and Abdominal Symptoms: A Hospital-based Cross-sectional Study. Intern Med. 2020; 59: 1677-1685. 48) Takeda T, Asaoka D, Abe D, Suzuki M, Nakagawa Y, Sasaki H, Inami Y, Ikemura M, Utsunomiya H, Oki S, Suzuki N, Ikeda A, Yatagai N, Komori H, Akazawa Y, Matsumoto K, Ueda K, Ueyama H, Shimada Y, Matsu-moto K, Hojo M, Osada T, Nojiri S, Nagahara A: Linked color imaging improves visibility of reflux esophagitis. BMC Gastroenterol, 2020; 20: 356. 49) Nakajima A, Habu S, Kasai M, Okumura K, Ishikawa D, Shibuya T, Kobayashi O, Osada T, Ohkusa T, Watanabe S, Nagahara A: Impact of maternal dietary gut microbial metabolites on an offspring’s systemic 3 immune response in mouse models. Bioscience of Microbiota, Food and Health, 2020; 39: 33-38. 50) Okahara K, Ishikawa D, Nomura K, Lee SY, Itou S, Haga K, Takahashi M, Shibuya T, Osada T, Nagahara A: Matching between Donors and Ulcerative Colitis Patients Is Important for Long-Term Maintenance after Fecal Micro-biota Transplantation. J Cli Med, 2020; 9: 1650. 51) Shibuya T, Haga K, Saeki M, Haraikawa M, Tsuchihashi H, Okahara K, Nomura O, Fukushima H, Murakami T, Ishikawa D, Ikeda S, Nagahara A: Pyoderma gangrenosum in an ulcerative colitis patient during treatment with vedolizumab responded favorably to adsorptive granulocyte and monocyte apher-esis. J Clin Apher, 2020; 35: 488-492. doi: 10. 1002/jca.21821. 52) Murakami T, Yao T, Yatagai N, Yamashiro Y, Saito T, Sakamoto N, Nagahara A: Colorectal adenocarcinoma with enteroblastic differenti-ation: a clinicopathological study of five cases. Histopathology, 2020; 76: 325-332. 53) Yamashiro Y, Saito T, Hayashi T, Murakami T, Yanai Y, Tsuyama S, Suehara Y, Taka-mochi K, Yao T: Molecular and clinicopatho-logical features of colorectal adenocarcinoma with enteroblastic differentiation. Histopa-431